甲状腺各腔镜手术安全性及疗效对比研究

注册号:

Registration number:

ChiCTR2400085590 

最近更新日期:

Date of Last Refreshed on:

2024-06-13 11:10:11 

注册时间:

Date of Registration:

2024-06-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

甲状腺各腔镜手术安全性及疗效对比研究

Public title:

Safety and rootfulness of endoscopic thyroidectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

甲状腺各腔镜手术安全性及疗效对比研究

Scientific title:

Safety and rootfulness of endoscopic thyroidectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴红吉 

研究负责人:

马驰 

Applicant:

Hongji Wu 

Study leader:

Chi Ma 

申请注册联系人电话:

Applicant telephone:

+86 178 6120 1981

研究负责人电话:

Study leader's
telephone:

+86 159 6517 3405

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1203593976@qq.com

研究负责人电子邮件:

Study leader's E-mail:

machi_sdu@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中华人民共和国山东省烟台市芝罘区毓璜顶东路20号

研究负责人通讯地址:

中华人民共和国山东省烟台市芝罘区毓璜顶东路20号

Applicant address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai City, Shandong Province, People's Republic of China

Study leader's address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai City, Shandong Province, People's Republic of China

申请注册联系人邮政编码:

Applicant postcode:

264000

研究负责人邮政编码:

Study leader's postcode:

264000

申请人所在单位:

青岛大学附属烟台毓璜顶医院

Applicant's institution:

The Affiliated Yantai Yuhuangding Hospital of Qingdao University

研究负责人所在单位:

青岛大学附属烟台毓璜顶医院

Affiliation of the Leader:

The Affiliated Yantai Yuhuangding Hospital of Qingdao University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-168

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

烟台毓璜顶医院伦理委员会

Name of the ethic committee:

Ethics committee of Yantai Yuhuangding Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-03-18 00:00:00

伦理委员会联系人:

张华

Contact Name of the ethic committee:

Hua Zhang

伦理委员会联系地址:

中华人民共和国山东省烟台市芝罘区烟台毓璜顶医院行政楼518会议室

Contact Address of the ethic committee:

Meeting Room 518, Administrative building, Yantai Yuhuangding Hospital, Zhifu District, Yantai City, Shandong Province, People's Republic of China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 136 2535 0817

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青岛大学附属烟台毓璜顶医院

Primary sponsor:

The Affiliated Yantai Yuhuangding Hospital of Qingdao University

研究实施负责(组长)单位地址:

中华人民共和国山东省烟台市芝罘区毓璜顶东路20号

Primary sponsor's address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai City, Shandong Province, People's Republic of China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

烟台

Country:

China

Province:

Shandong

City:

Yantai

单位(医院):

青岛大学附属烟台毓璜顶医院

具体地址:

中华人民共和国山东省烟台市芝罘区毓璜顶东路20号

Institution
hospital:

The Affiliated Yantai Yuhuangding Hospital of Qingdao University

Address:

No. 20, Yuhuangding East Road, Zhifu District, Yantai City, Shandong Province, People's Republic of China

经费或物资来源:

Source(s) of funding:

None

研究疾病:

甲状腺癌  

Target disease:

thyroid cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

本研究患者分为无充气经腋窝入路甲状腺切除术组(GETTA)和无充气经锁骨下入路腔镜甲状腺切除术组(GETTSA)。均行单侧甲状腺切除、峡部切除和中央颈清扫术,通过统计学分析,对此无充气经腋窝入路甲状腺切除术和无充气经锁骨下入路腔镜甲状腺切除术的各项指标,包括手术安全性和完整性以及其他手术特征和住院特征等进行比较。  

Objectives of Study:

The patients in this study were divided into the group of gasless endoscopic thyroidectomy transaxillary approach (GETTA) and gasless endoscopic thyroidectomy transsubclavian approach (GETTSA). All underwent unilateral thyroidectomy, isthmus resection and central neck dissection, for which various parameters, including surgical safety and completeness, as well as other surgical and hospitalisation characteristics, were compared between gasless endoscopic thyroidectomy transaxillary approach and gasless endoscopic thyroidectomy transsubclavian approach by statistical analysis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(a)颈部手术史,(b)颈部放射治疗史,(c)颈侧淋巴结转移,(d)肿瘤侵犯邻近器官,(e)合并远处转移

Exclusion criteria:

(a) history of neck surgery, (b) history of neck radiation therapy, (c) lateral neck lymph node metastasis, (d) tumour invasion into adjacent organs, and (e) combined distant metastasis

研究实施时间:

Study execute time:

From 2024-06-20 00:00:00 To 2025-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-20 00:00:00 To 2025-06-01 00:00:00

干预措施:

Interventions:

组别:

GETTA组:无充气经腋窝入路甲状腺切除术

样本量:

100

Group:

GETTA group: gasless endoscopic thyroidectomy transaxillary approach

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

GETTSA组:无充气经锁骨下入路甲状腺切除术

样本量:

100

Group:

GETTSA group: gasless endoscopic thyroidectomy transsubclavian approach

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

烟台 

Country:

China

Province:

Shandong

City:

Yantai

单位(医院):

青岛大学附属烟台毓璜顶医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Yantai Yuhuangding Hospital of Qingdao University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

中央区淋巴结转移数目

指标类型:

主要指标

Outcome:

the number of central lymph node metastases

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

主要指标

Outcome:

postoperative complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间

指标类型:

次要指标

Outcome:

duration of operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院时间

指标类型:

次要指标

Outcome:

postoperative hospital stays

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据将于2025-06-01于临床试验公共管理平台(http://www.medresman.org.cn/)共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data will be shared on 2025-06-01 on the Clinical Trial Management Public Platform (http://www.medresman.org.cn/)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

做好病例记录表(Case Record Form, CRF)和电子采集和管理系统(Electronic Data Capture, EDC)的数据整理工作,使用ResMan(一种基于互联网的EDC)(http://www.medresman.org.cn/)。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Do a good job of organising data in the Case Record Form (CRF) and Electronic Data Capture and Management System (EDC).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-06-13 11:10:06